Corrects name of unit in headline, paragraphs 1 and 4 to biosciences and diagnostic solutions from life sciences. The error also appeared in an earlier version of the story
Feb 5 (Reuters) - Becton Dickinson BDX.N beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device maker aims to focus on its core business.
"We believe the separation will position New BD as a differentiated MedTech leader and enable optimized investment," said CEO Tom Polen.
The company expects to announce more details on the separation plans by the end of fiscal 2025.
Becton's biosciences and diagnostic solutions unit makes diagnostic products such as those used to detect infectious diseases and cancers.
Earlier this week, the Financial Times reported activist investor Starboard Value had taken a stake in Becton and was pushing the company to sell its life sciences unit.
The company also raised the lower end of its fiscal 2025 profit forecast to a range of $14.30 to $14.60 per share, compared to the previous range of $14.25 to $14.60 each.
Becton's total sales for the reported quarter came in at $5.17 billion, above analysts' estimates of $5.1 billion, according to data compiled by LSEG.
On an adjusted basis, the company reported a per-share profit of $3.43, beating analysts' average expectation of $2.98.
(Reporting by Kamal Choudhury, Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Alan Barona)
((Kamal.Choudhury@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。